Read More
Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.
Read More
>>Hollywood's Exotic Secret For Healthy Weight Loss
Read More
Subscribe to:
Post Comments (Atom)
0 Response to "Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy"
Post a Comment